54 results on '"Westerhout, Cynthia M."'
Search Results
2. Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat
3. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial
4. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment–Elevation Myocardial Infarction: A Randomized, Open-Label Trial
5. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment–Elevation Myocardial Infarction: A Randomized, Open-Label Trial
6. Abstract 11603: Comparing Analytical Methods for Composite Endpoints in Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial
7. Abstract 11574: Relationship Between Baseline Electrocardiographic Parameters and Outcomes in Patients With High-Risk Heart Failure With Reduced Ejection Fraction: Insights From the Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial
8. Abstract 11453: Age, Sex, and Outcomes in Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial
9. Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)
10. The Titration and Tolerability of Sacubitril/Valsartan for Patients with Heart Failure in Clinical Practice
11. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice: Insights From the Vital Heart Response Registry
12. Corrigendum to “Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial” [Am Heart J 169/6 (2015) 890–898]
13. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial
14. Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction
15. Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis
16. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged
17. Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial
18. Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: Insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial
19. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial
20. Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial
21. Routine invasive management early after fibrinolysis: Relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials
22. Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: Insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial
23. The forgotten lead: Does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients?
24. Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint
25. Aborted myocardial infarction after primary percutaneous coronary intervention: Magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
26. Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial
27. Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase
28. Mode of hospital presentation in patients with non-ST-elevation myocardial infarction: Implications for strategic management
29. Refining clinical trial composite outcomes: An application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial
30. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: A pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST
31. Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non–ST-segment elevation acute coronary syndromes
32. Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial
33. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial
34. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial
35. Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
36. Resolution of ST-segment depression: a new prognostic marker in ST-segment elevation myocardial infarction
37. Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction:: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
38. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study
39. Guideline adjudicated fibrinolytic failure: Incidence, findings, and management in a contemporary clinical trial
40. Differences in admission rates and outcomes between men and women presenting to emergency departments with coronary syndromes
41. The authors’ reply
42. A Novel Enoxaparin Regime for St Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: a West Sub-Study
43. Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women
44. No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: Insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial
45. Primary Percutaneous Coronary Intervention Compared With Fibrinolysis for Myocardial Infarction in Diabetes Mellitus: Results From the Primary Coronary Angioplasty vs Thrombolysis–2 Trial
46. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups
47. Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes
48. Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction
49. Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis
50. Radial versus femoral access, bleeding and ischemic events in patients with non–ST-segment elevation acute coronary syndrome managed with an invasive strategy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.